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Abstract Chromogranin B (CgB) is a member of the granin
family of neuroendocrine secretory proteins, which has been
proposed to play a role in secretory granule biogenesis and as a
precursor to bioactive peptides. The cloning of CgB in a
phylogenetically distant vertebrate, the frog Rana ridibunda,
reveals a modest overall homology (35^40%) with mammalian
CgB. However, the sequences of the N- and C-terminal regions
are more highly conserved (57^65% amino acid identity) and
may give rise to novel regulatory peptides. In frog, intense
expression of CgB mRNA was observed in particular structures
of the brain and in the distal lobe of the pituitary. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The granin protein family includes several acidic glycopro-
teins that are localized in secretory granules of endocrine,
neuroendocrine and neuronal cells. Chromogranin A (CgA),
chromogranin B (CgB) and secretogranin II (SgII) are mem-
bers of this family whose biochemical and biological proper-
ties have been extensively studied in mammals [1,2]. Granins
have been ¢rst described as major proteins co-stored and co-
secreted with hormones and neurotransmitters upon activa-
tion of the regulated secretory pathway in endocrine and neu-
roendocrine cells [3].
The primary structure of granins has been determined
through molecular cloning of the corresponding cDNAs
[1,2,4]. These studies have revealed several commonalties be-
tween the granin protein family members, including a high
proportion of acidic amino acids (up to 30%) and the occur-
rence of numerous pairs of basic amino acids which represent
potential cleavage sites for prohormone convertases. Indeed,
processing of granins within secretory vesicles is now well
evidenced and gives rise to a variety of peptides that are
also secreted upon stimulation [1^4]. The biochemical and
biological characteristics of the granin family indicate that
these proteins may play fundamental roles in the biogenesis
of neuroendocrine secretory granules and may serve as pre-
cursors to several biologically active peptides [1^4].
We have previously characterized two members of the gra-
nin family, namely SgII and CgA, in a submammalian species,
the frog Rana ridibunda, and we have observed that the se-
quences of discrete regions within these proteins £anked by
dibasic cleavage sites have been highly preserved from am-
phibians to mammals [5]. Some of these conserved potential
peptides have been actually characterized in di¡erent neuro-
endocrine tissues and have been shown to exert biological
activities in the central nervous system or in peripheral organs
[6,7].
Despite intense investigation on granins, the sequence of
CgB has only been determined in mammalian species [1,2].
Determination of the primary structure of CgB and character-
ization of the expression pattern of its gene in a phylogeneti-
cally distant species may help to de¢ne the function of this
protein. In the present study, we have cloned CgB in frog in
order to compare its sequence and its distribution to those of
its mammalian homologs.
2. Materials and methods
2.1. Polymerase chain reaction (PCR) cloning
Frog brain, pituitary and adrenal RNA (5 Wg) was reverse tran-
scribed at 42‡C for 50 min with 200 U of Moloney murine leukemia
virus RNase H3 superscript in the presence of 0.5 Wg oligo(dT)12ÿ18 in
the bu¡er supplied with the enzyme (Life Technologies, Cergy-Pon-
toise, France). PCR was performed on an aliquot of the reverse tran-
scriptase (RT) reaction in the presence of the degenerate sense primer
CGB5, 5P-GA(A/G)TT(C/T)CC(A/C/G/T)GA(C/T)TT(C/T)TA(C/T)-
GA(C/T)-3P and antisense primer CGB6, 5P-AA(C/T)TT(C/T)TC(A/
C/G/T)AT(C/T)TT(C/T)TG-3P, corresponding respectively to the ami-
no acid sequences EFPDFYD and QKIAEKF in the C-terminus, and
2.5 U Taq DNA polymerase (Life Technologies). Ampli¢cation was
achieved through 30 cycles of 94‡C for 1 min, 48‡C for 1 min and
72‡C for 1 min in a GeneAmp PCR System 9700 (Applied Biosys-
tems, Norwalk, USA). PCR products were electrophoresed on a 2%
agarose gel and a DNA fragment with the expected size (165 bp) was
puri¢ed and ligated into the pGEMT vector (Promega, Charbon-
nie'res, France). Sequencing revealed that this PCR product was highly
homologous to the corresponding C-terminal sequence of mammalian
CgB.
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2.2. cDNA library screening and sequence analysis
A frog (R. ridibunda) pituitary cDNA library made in the CDM7/
amp plasmid was screened with the oligonucleotide CGB7 5P-
AGCGATCTTCTGCAACTCCAGGTCCATAATTGCCAGGTTC-
TCCAATTC-3P, whose sequence was deduced from the PCR DNA
fragment. This oligonucleotide was 3P end-labeled with [K-32P]dCTP
(Amersham Pharmacia Biotech, Les Ulis, France) using terminal de-
oxynucleotide transferase (Promega). After prehybridization, ¢lters
were hybridized with 32P-labeled CGB7 as described previously [8].
A positive clone, FPL221, was sequenced on both strands on a LI-
COR 4000L DNA sequencer (ScienceTec, Les Ulis, France) using the
Thermosequenase kit (Amersham Pharmacia Biotech), £uorescent
universal primers and internal speci¢c primers (MWG Biotech, Ebers-
berg, Germany). Nucleotide and deduced amino acid sequences were
analyzed using the DNASIS v2.1 software (Hitachi, Olivet, France).
Prediction of the secondary structures of the frog and human CgB
proteins was performed at the NPS@ server (npsa-pbil.ibcp.fr) which
allows to determine consensus secondary structures of a protein based
on several predictions achieved by di¡erent algorithms (PHD, HNNC,
Predator, SIMPA96, SOPM, etc.).
2.3. Northern blot analysis
Total RNA from frog tissues was prepared by the acid guanidinium
thiocyanate-phenol-chloroform method [9] using the Tri reagent (Sig-
ma, Saint-Quentin Fallavier, France). RNA (10^20 Wg) was dissolved
in denaturing bu¡er, heated at 65‡C for 15 min, and fractionated on a
formaldehyde-agarose gel. After staining with ethidium bromide, the
gel was blotted on Hybond NX membrane (Amersham Pharmacia
Biotech) that was subsequently hybridized at 42‡C with a 32P-labeled
random primed (Prime-a-Gene labeling System, Promega) probe as
described previously [10].
2.4. RT-PCR
Approximately 5 Wg of total RNA isolated from various frog tissues
was reverse transcribed by using an oligo(dT)12ÿ18 primer and the
superscript II reverse transcriptase RNase H3 (Life Technologies).
PCR ampli¢cation was performed with 5 U of Taq DNA polymerase
(Life Technologies), and 50 pmol of the sense (CGB-S, 5P-GC-
AAGGTCATCACGAAGA-3P) and antisense (CGB-AS, 5P-AGCT-
GAGCCAGTTCATCC-3P) oligonucleotides in the GeneAmp PCR
System 9700 (Applied Biosystems) for 30 cycles of denaturation at
94‡C for 40 s, annealing at 50‡C for 1 min and extension at 72‡C
for 40 s.
2.5. In situ hybridization histochemistry
Frogs were anesthetized with MS 222 (Sigma) and perfused trans-
cardially with 4% paraformaldehyde. Brains were embedded in O.C.T.
Tissue Teck (Nussloch, Germany) and frontal sections (12 Wm thick)
were cut in a cryostat (Frigocut, Reicher-Jung, Germany). Tissue
sections were hybridized with 107 cpm/ml 35S-labeled riboprobe as
previously described [11]. Sense and antisense riboprobes were pre-
pared by in vitro transcription of a NcoI/SpeI fragment (nucleotides
950^1705) subcloned into pGEMT (Promega), in the presence of
[35S]UTP (Amersham Pharmacia Biotech) and T7 or SP6 RNA poly-
merase (Promega). Tissue sections were dehydrated and exposed onto
Hyper¢lm L max (Amersham Pharmacia Biotech) for 4 days. Ana-
tomical structures were identi¢ed by staining tissue slices with hema-
toxylin and eosin.
3. Results
3.1. Characterization and analysis of the frog CgB sequence
Several pairs of degenerate oligonucleotides deduced from
mammalian CgB sequences were used in order to amplify by
PCR a DNA fragment from reverse transcribed RNA. One
pair of primers deduced from the C-terminal sequence of
mammalian CgB proteins allowed to amplify a DNA frag-
ment of the expected size from frog adrenal gland reverse
transcribed RNA (data not shown). Cloning and sequencing
revealed that this PCR product encodes an amino acid se-
quence that is highly homologous to the mammalian CgB
C-terminal sequence.
Fig. 1. Primary structure and sequence alignment of frog CgB. A: The frog prepro-CgB protein contains a 19 amino acid signal peptide (SP)
and a 580 amino acid mature protein that encompasses 27.7% acidic residues. The positions of the di- or tribasic residues are indicated, the
two cysteines forming the disul¢de bridge are circled and the potential N-glycosylation site is boxed. The CgB-derived peptides PE-11 [22], se-
cretolytin [24], CCB [20] and BAM-1745 [21] that have been described in mammals, and their locations are also indicated. B: The frog CgB
amino acid sequence was aligned with the human (GenBank accession number AAH00375), bovine (accession number AAC48720), porcine (ac-
cession number AAG13399), rat (accession number AAB72089) and mouse (accession number CAA37199) sequences. The amino acids of frog
CgB that are conserved in the other species are in dark boxes. The hyphens represent gaps that have been introduced for the alignment. The
numbers refer to the frog sequence.
6
Fig. 2. Comparison of the sequence of the frog CgB protein with those of the human CgB protein and frog CgA protein. A: Schematic repre-
sentation of CgB showing the percentages of amino acid identity between conserved dibasic residues in the frog and human proteins. B: Sche-
matic representation of frog CgA and CgB showing the percentages of identity in the N- and C-terminal regions.
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Based on the PCR product sequence, an oligonucleotide
was synthesized and used to isolate full-length clones from a
frog pituitary cDNA library.
Analysis of a positive clone revealed that the cDNA con-
tained an open reading frame of 1797 bp encoding a 599
amino acid pre-protein (Fig. 1A). The ¢rst 19 amino acids
correspond to the signal peptide and the remaining 580 amino
acids represent the mature frog CgB protein with a predicted
molecular mass of 70 kDa. The calculated pI is 5.32 which
re£ects the abundance of acidic residues (27.7%) in the CgB
sequence, consisting of 21.2% Glu and 6.5% Asp. Frog CgB
contains a putative N-glycosylation site at position 490 and
two cysteine residues located at positions 16 and 37 which are
known to form a disul¢de bridge in the mammalian protein
[2]. It is interesting to note that the number of amino acids
separating the two cysteines (20 residues) is identical in all
CgB sequences characterized to date. The amino acid se-
quence of frog CgB also comprises 20 di- or tribasic potential
cleavage sites (Fig. 1A and B).
Sequence alignment of frog CgB with its mammalian ortho-
logues shows an overall amino acid sequence identity of only
35^40% (Fig. 1B). However, a much higher degree of similar-
ity was observed in the N- and C-terminal regions of the
protein (Fig. 1B). These conserved domains exhibit 60^65%
amino acid identity between the frog and human sequences,
whereas the central region of the molecule shows less than
25% similarity (Fig. 2A). It is worth noting that the conserved
regions are delimited by preserved pairs of basic residues (Fig.
2A). The comparison of the sequences of frog CgB and frog
CgA, that we have previously characterized [8], showed some
degree of homology in the N- and C-terminal regions which
exhibit 36 and 45% sequence identity, respectively (Fig. 2B).
3.2. Tissue distribution of frog CgB mRNA
The expression and abundance of CgB mRNA in di¡erent
frog tissues was studied by Northern blot and RT-PCR anal-
ysis. A single CgB transcript of approximately 2.5 kb was
detected by Northern blot analysis in the brain, spinal cord
and pituitary (Fig. 3A). The expression of CgB mRNA was
much higher in the brain and pituitary than in the spinal cord
(Fig. 3A). RT-PCR analysis revealed the presence of the CgB
transcript also in the adrenal gland, stomach, pancreas and
intestine (Fig. 3B). Unexpectedly, CgB mRNA was also de-
tected in non-neuroendocrine tissues such as heart, liver,
spleen and kidney (Fig. 3B). When reverse transcriptase was
omitted in the RT-PCR experiments, no DNA ampli¢cation
was observed in any of the tissues examined (Fig. 3B).
3.3. Localization of CgB mRNA in the frog brain
In situ hybridization histochemistry revealed the widespread
distribution of CgB mRNA in the frog central nervous system
(Fig. 4). In the telencephalon, intense labeling was observed in
the lateral pallium and the postolfactory eminence, while the
internal granular layer of the olfactory bulb and the median
pallium contained a lower concentration of CgB transcript
(Fig. 4A, B). The dorsal striatum and the medial amygdala
were more strongly labeled than the ventral striatum and the
medial or lateral septum (Fig. 4C, D). In the diencephalon, an
intense hybridization signal was observed in the anterior pre-
optic area (Fig. 4C), the dorsal hypothalamic nucleus and the
nucleus of the periventricular organ (Fig. 4E). A moderate
signal was observed in the ventral hypothalamic nucleus and
the thalamic nuclei where only a few cells were strongly la-
beled (Fig. 4E, F). In the mesencephalon, CgB mRNA was
abundant in the optic tectum and in the anteroventral tegmen-
tal nucleus, whereas the anterodorsal tegmental nucleus and
the torus semicircularis displayed only background hybridiza-
tion signal (Fig. 4G). In the pituitary, intense expression was
observed in the distal lobe, while the intermediate lobe was
totally devoid of CgB mRNA (Fig. 4G, H). In the spinal cord,
both the dorsal and ventral horns were labeled (Fig. 4I, J).
When a sense probe was used, no hybridization signal was
observed (Fig. 4K).
4. Discussion
This study has described the ¢rst molecular characterization
of CgB in a non-mammalian vertebrate, the frog R. ridibunda.
The predicted frog CgB protein exhibits the common charac-
teristics of granins such as the presence of multiple pairs of
basic residues (20 dibasic motifs) and a high content of acidic
amino acids (27.7%). Alignment of the frog CgB protein with
its mammalian homologs [12,13] revealed a rather low overall
amino acid sequence identity (V35%). However, the N- and
C-terminal regions were more highly conserved (V60%) than
the internal region which exhibited a remarkable sequence
variation (V20%). In mammalian species, the N- and C-ter-
minal portions of CgB exhibit V90% sequence identity and
the central region shows V60% sequence similarity [2]. It thus
appears that the N- and C-terminal extremities of CgB have
been selectively conserved during evolution while the middle
portion of the protein has diverged more rapidly. In addition,
a bioinformatic analysis revealed that consensus secondary
structures predicted by di¡erent algorithms in the N- and
C-terminal domains of the mature frog CgB protein are pre-
served in the human CgB protein, whereas the secondary
structures predicted in the central portion of the molecule
Fig. 3. Tissue distribution of frog CgB mRNA. A: Northern blot
analysis was performed on total RNA extracted from the brain, spi-
nal cord and pituitary that was hybridized to a 32P-labeled CgB
probe. The positions of 28S and 18S ribosomal RNA are indicated
and their staining by ethidium bromide is shown under the autora-
diogram. B: RT-PCR analysis of CgB mRNA expression in di¡er-
ent frog tissues. RNA from these tissues was analyzed in the pres-
ence (+) or absence (3) of RT.
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markedly di¡er in the two proteins (not shown). In frog as in
mammals, the N-terminal portion of CgB exhibits two K-heli-
ces separated by a random coil structure and the C-terminal
region displays a predominant K-helical structure. In contrast,
while the central region of the frog protein is enriched in
K-helices that alternate with random coils, the internal portion
of human CgB mainly consists of random coil secondary
structures. Consequently, the overall content of K-helix and
random coil structures are 58 and 36%, respectively, for the
frog protein and 31 and 62%, respectively, for the human
protein. The strong conservation of the sequence and the sec-
ondary structure of the N- and C-terminal regions of CgB in
vertebrates reinforces the idea that these segments are critical
for the function of this protein.
The N-terminal region of CgB and the conserved disul¢de-
bonded loop it contains, have been shown to be important for
the interaction of this protein with trans-Golgi network mem-
branes and its sorting to secretory granules [14]. It has re-
cently been shown that reduction of CgB expression does
not a¡ect secretory granule formation while depletion of
CgA provokes the disappearance of secretory vesicles in neu-
roendocrine cells, indicating that CgA, but not CgB, plays a
critical role in the biogenesis of dense-core secretory granules
[15] and that CgB cannot compensate for the absence of ex-
pression of CgA although the two granins exhibit structural
and biochemical similarities. However, CgB may play a di¡er-
ent role in secretory granule and neuroendocrine cell biology.
For instance, it has been shown that CgB and CgA in hetero-
tetramers can interact with the intraluminal loop of the ino-
sitol 1,4,5-triphosphate (IP3) receptor/calcium channel allow-
ing the release of calcium which is bound to the granins in
secretory vesicles [16]. This interaction involves the N-termi-
nal domains of CgA and CgB which are conserved between
frog and mammals.
The cloning of frog CgB also revealed the conservation of
the C-terminal sequence and the dibasic cleavage sites it con-
Fig. 4. In situ hybridization analysis of CgB gene expression in the frog central nervous system. The autoradiograms obtained from frontal
brain slices at the level of the telencephalon (A), telencephalon/diencephalon (C, E), mesencephalon (G) and spinal cord (I) are shown. Hybridi-
zation with the sense probe is shown on a section at the level of the telencephalon/diencephalon (K). L: Schematic drawing of a parasagittal
view of the frog brain showing the levels of the frontal sections. The anatomical structures are indicated beside each section. Emulsion photo-
micrographs of selected areas of sections in A, C, E, G and I are shown in B, D, F, H and J, respectively. Abbreviations: AD, anterodorsal
tegmentum; AOB, accessory olfactory bulb; AV, anteroventral tegmentum; CNT, central thalamic nucleus; DH, dorsal hypothalamic nucleus;
DP, dorsal pallium; Dst, dorsal striatum; HD, dorsal horn; HV, ventral horn; IGL, intragranular layer of the olfactory bulb; LP, lateral pal-
lium; LS, lateral septum; MA, medial amygdala; MP, medial pallium; MS, medial septum; NPv, nucleus of the periventricular organ; P, pos-
terior thalamic nucleus; Pdis, pars distalis ; PE, postolfactory eminence; PI, pars intermedia; POA, anterior preoptic area; TS, torus semicircu-
laris; Vst, ventral striatum.
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tains, suggesting that this region can be processed to generate
peptides which may exert biological activities in di¡erent spe-
cies as it has been shown for SgII- or CgA-derived peptides
[6,7,17^19]. In fact, most of the CgB-derived peptides that
have been identi¢ed so far are derived from the C-terminal
part of the protein (see Fig. 1). These include two peptides
named GAWK and CCB that have been isolated from the
human pituitary gland [20], a pyroglutamyl peptide named
BAM-1745 that has been puri¢ed from bovine adrenochro-
ma⁄n cell secretory granules [21] and an 11 amino acid pep-
tide named PE-11 that has been identi¢ed in the rat and the
human brain [22,23]. To date, no function has been attributed
to these four peptides. Another peptide corresponding to the
sequence 614^626 of CgB has been characterized from the
bovine adrenal medulla [24]. This 13 amino acid peptide exerts
antibacterial activity and has been named secretolytin. The
sequence of secretolytin as well as those of BAM-1745 and
CCB have been particularly well conserved during evolution,
suggesting that these peptides may play important biological
functions.
A single mRNA species encoding CgB has been character-
ized in frog and is highly expressed in the brain and pituitary.
High concentrations of CgB mRNA were observed in several
areas of the frog brain including the lateral pallium, the dorsal
hypothalamic nucleus and the anteroventral tegmentum, in
agreement with the widespread expression of CgB mRNA
that has been reported in the mammalian brain [2]. In frog,
CgB mRNA was also detected in various neuroendocrine tis-
sues including the adrenal, the pancreas or the stomach. In
particular, intense expression of CgB mRNA was observed in
the distal lobe but not in the intermediate lobe of the pitui-
tary, suggesting that CgB and/or derived peptides may play a
role in speci¢c hypophysial activities. Expression of the CgB
transcript was also detected in other frog peripheral organs
including the heart, kidney and spleen. In mammals, chro-
mogranin immunoreactivity has been described in the rat
heart [25] where it seems to localize to muscle cells of the atria
[26] and in paraganglionic cells present in the human kidney
[27]. Further studies with more sensitive techniques are re-
quired to identify and con¢rm the types of cells expressing
CgB mRNA in non-endocrine tissues including the liver,
spleen and kidney.
In conclusion, this study has described the characterization
of a non-mammalian CgB, revealing the high conservation of
the N- and C-terminal regions of the protein. These conserved
domains may represent structural determinants underlying an
intravesicular role of CgB. Alternatively, these regions may
give rise to peptides that exert biological activities after release
from endocrine, neuroendocrine and neuronal cells where the
CgB gene is widely expressed.
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